Kummerfeld Keith C
Known title: See RemarksCIK: 0001762749
Associated companies
Transaction History
| ARCT | ▲ Buy | Option Exercise | 4,500 | $41K | 7/14/2023 | View on chart |
| ARCT | ▲ Buy | Option Exercise | 1,437 | $7K | 7/14/2023 | View on chart |
| ARCT | ▲ Buy | Option Exercise | 1,031 | $15K | 7/14/2023 | View on chart |
| ARCT | ▼ Sell | Open Market | 6,968 | $244K | 7/14/2023 | View on chart |
| ARCT | ▲ Buy | Option Exercise | 1,031 | $15K | 4/18/2023 | View on chart |
| ARCT | ▲ Buy | Option Exercise | 4,500 | $41K | 4/18/2023 | View on chart |
| ARCT | ▲ Buy | Option Exercise | 1,437 | $7K | 4/18/2023 | View on chart |
| ARCT | ▼ Sell | Open Market | 6,968 | $196K | 4/18/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Arcturus Shares Rise on Phase II Data and Analyst Upgrades
Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.
Arcturus Shares Rise on Phase II Data and Analyst Upgrades. Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.